Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in
the treatment of ulcers related to diabetic foot syndrome
Phase:
N/A
Details
Lead Sponsor:
Human Stem Cell Institute, Russia
Collaborators:
Ryazan State Medical University Ryazan State Medical University named after academician I.P. Pavlov Saint-Petersburg state hospital №14 Vidnoe District Hospital